Xeris Pharmaceuticals
- Market cap
- 1.84B
- P/E (TTM)i
- -104.23
- P/Bi
- -190.75
- EPSi
- 0.00
- Div yieldi
- 0.00%
- 52W posi
- 80%
Anonymous reader poll. Unscientific, not investment advice.
Xeris Pharmaceuticals last traded at 10.11, up 0.40% on the session. At current prices, the business is worth about 1.84B, the #2862 most valuable US-listed company we track. Trading at a P/E of -103.81, the stock is 259% below its own five-year norm of 65.13. The 5 analysts covering the stock are, on balance, at Buy, targeting an average of 12.00 (+19%). Over the past year the stock has ranged from 5.25 to 11.33; it now sits 80% up that band.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 weeks.
- Recent price momentum is +17.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 4.4% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 59.3x | Better than 7% |
| Price / Sales | 5.5x | Better than 25% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 85.4% | Better than 95% |
| Operating margin | 8.5% | Better than 30% |
| Net margin | 0.2% | Better than 14% |
| Return on equity | -324.2% | Better than 1% |
| Return on invested capital | -17.5% | Better than 5% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 13.3% | Better than 80% |
| 6-month return | 72.6% | Better than 94% |
| 12-month return (ex latest month) | 4.9% | Better than 38% |
| Distance below 52-week high | 10.6% | Better than 74% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.2x | Better than 71% |
| Debt to assets | 67.3% | Better than 17% |
| Interest coverage | 1.0x | Better than 14% |
| Free cash flow / net income | 5,041.5% | Better than 100% |
Analyst View C+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 80.0% | Better than 58% |
| Upside to average target | 14.5% | Better than 25% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 10.07
- Open
- 10.00
- Day range
- 9.91 - 10.27
- Avg price
- 10.14
- Volume
- 2.22M
- Turnover
- 22.53M
- Turnover ratei
- 1.26%
- Volume ratioi
- 0.68
- Amplitudei
- 3.58%
- 52-week rangei
- 5.25 - 11.33
Valuation
- P/Ei
- 3,370.00
- P/E (TTM)i
- -104.23
- P/Bi
- -190.75
- EPSi
- 0.00
- Book value / shi
- -0.05
- Net profit
- 546.96K
- Net assets
- -9.66M
Share structure
- Market cap
- 1.84B
- Float capi
- 1.78B
- Shares out
- 182.32M
- Float sharesi
- 176.07M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-06-21
10.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-14.18M net over the window
Short interest
- Shares short
- 8.06M
- % of floati
- 4.42%
- Days to coveri
- 4.83
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Xeris Pharmaceuticals (XERS)?
Xeris Pharmaceuticals last traded at 10.11. The quote on this page refreshes every few seconds while US markets are open.
What is Xeris Pharmaceuticals's market cap?
About 1.84B.
What is the P/E ratio of Xeris Pharmaceuticals?
The trailing twelve-month P/E is -104.23, below its own 5-year average of 65.13 — toward the bottom of its historical range (0.16% percentile). See the Valuation tab for the full history.
Does Xeris Pharmaceuticals pay a dividend?
Xeris Pharmaceuticals does not currently pay a regular dividend.
Is Xeris Pharmaceuticals a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 12.00, which implies 18.7% upside from the current price. This is not investment advice.
What is Xeris Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Xeris Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 08:03:22 · For reference only, not investment advice and not tailored to your situation.